Clear all
2018 • Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Works in BIP! associated with the specified OpenAIRE research product

Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tam (...)
Haematologica · 2018
Internal medicine |         Oncology |